Cancer Letters
Volume 291, Issue 2 , Pages 177-186, 28 May 2010

PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells

  • Jian Yu

      Affiliations

    • The First Affiliated Hospital of Zhejiang University Medical School, Hangzhou 310003, China
    • Anhui Key Laboratory for Cellular Dynamics and Chemical Biology and National Laboratory for Physical Sciences at Nanoscale, Hefei 230027, China
    • These authors contributed equally to this work.
  • ,
  • Jianping Lan

      Affiliations

    • The First Affiliated Hospital of Zhejiang University Medical School, Hangzhou 310003, China
    • Department of Hematology, Zhejiang Provincial People’s Hospital, Hangzhou 310014, China
    • Anhui Key Laboratory for Cellular Dynamics and Chemical Biology and National Laboratory for Physical Sciences at Nanoscale, Hefei 230027, China
    • These authors contributed equally to this work.
  • ,
  • Chong Wang

      Affiliations

    • The First Affiliated Hospital of Zhejiang University Medical School, Hangzhou 310003, China
  • ,
  • Quan Wu

      Affiliations

    • Anhui Key Laboratory for Cellular Dynamics and Chemical Biology and National Laboratory for Physical Sciences at Nanoscale, Hefei 230027, China
  • ,
  • Yuanyuan Zhu

      Affiliations

    • The First Affiliated Hospital of Zhejiang University Medical School, Hangzhou 310003, China
  • ,
  • Xiaoyu Lai

      Affiliations

    • The First Affiliated Hospital of Zhejiang University Medical School, Hangzhou 310003, China
  • ,
  • Jie Sun

      Affiliations

    • The First Affiliated Hospital of Zhejiang University Medical School, Hangzhou 310003, China
  • ,
  • Changjiang Jin

      Affiliations

    • Anhui Key Laboratory for Cellular Dynamics and Chemical Biology and National Laboratory for Physical Sciences at Nanoscale, Hefei 230027, China
    • Corresponding Author InformationCorresponding authors. Tel./fax: +86 571 8723 6706 (H. Huang), +86 551 360 7141 (C. Jin).
  • ,
  • He Huang

      Affiliations

    • The First Affiliated Hospital of Zhejiang University Medical School, Hangzhou 310003, China
    • Corresponding Author InformationCorresponding authors. Tel./fax: +86 571 8723 6706 (H. Huang), +86 551 360 7141 (C. Jin).

Received 17 May 2009; received in revised form 11 October 2009; accepted 13 October 2009. published online 09 November 2009.

Abstract 

Telomerase-negative cancer cells maintain their telomeres by a mechanism known as alternative lengthening of telomeres (ALT) and achieve unlimited replicative potential. A hallmark of ALT cells is the recruitment of telomeres to promyelocytic leukemia (PML) bodies and formation of ALT-associated PML bodies (APBs). Although the exact molecular mechanism of APBs assembly remains unclear, APBs assembly requires telomere and PML body-associated proteins, including TRF1 and PML. Here, we report that PML3, one of PML isoforms, is involved in APBs formation. As a new binding protein of TRF1 (telomeric repeat binding factor 1), PML3 directly interacts with TRF1 and recruits TRF1 to PML bodies in U2OS cells. More notably, depletion of PML3 by small interfering RNA does not affect PML bodies formation, but inhibits the recruitment of both TRF1 and TRF2 to APBs. Further study shows that the recruitment of TRF1 to APBs depends on its interaction with a specific PML3 isoform. Thus, the interaction of PML3 with TRF1 is isoform specific and likely to be essential for APBs assembly in U2OS cells.

Keywords: Alternative lengthening of telomeres, ALT-associated PML bodies, TRF1, PML3

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(09)00631-4

doi:10.1016/j.canlet.2009.10.009

Cancer Letters
Volume 291, Issue 2 , Pages 177-186, 28 May 2010